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Abstract
Objective A recurrent observation is that associations between self-reported and objective medication adherence measures 
are often weak to moderate. Our aim was therefore to identify patients with different profiles on self-reported and objective 
adherence measures.
Study Design and Setting This was an observational study of 221 community pharmacy patients who were dispensed anti-
depressants. Adherence profiles were estimated with Latent Profile Analysis (LPA) using data on self-reported adherence 
(Medication Adherence Rating Scale) complemented with data on medication beliefs (perceived necessity and concerns 
measured with the Beliefs about Medicines Questionnaire) and data from objective adherence measures (electronic monitor-
ing of medication taking and the Medication Possession Ratio calculated from pharmacy dispensing data).
Results ‘Goodness-of-fit’ statistics indicated the presence of three classes: “concordantly high adherent” (83%, high adher-
ence on all measures), “concordantly suboptimal adherent” (11%, low adherence on all measures), and “discordant” (6%, 
high self-reported adherence but lower adherence on objective measures).
Conclusion Most patients had concordant outcomes on self-reported and objective measures of adherence. A small discordant 
class had high self-reported but low objective adherence. LPA will enable sensitivity analyses in future studies, for example 
excluding patients from the discordant class.
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Key Points 
Using Latent Profile Analysis, this study found three 
distinct profiles on subjective and objective measures of 
medication adherence: a “concordantly high adherent” 
profile, a “concordantly suboptimal adherent” profile, 
and a “discordant” profile of high self-reported adher-
ence but low objective adherence.
Latent Profile Analysis of adherence measures demon-
strates that researchers and clinicians should not rely on 
a single adherence measure, but rather should conduct 
rigorous sensitivity analyses of data on multiple adher-
ence measures.
1 Introduction
A recurrent observation in the medication adherence lit-
erature is that associations between different measures 
of adherence tend to be weak to moderate [1–3]. Avail-
able measures of medication adherence include subjective 
assessment methods such as questionnaires for self-reported 
adherence. Opposed to these are objective measures such 
as those inferred from pharmacy dispensing data and elec-
tronic monitoring of medication intake with a device. The 
co-existence of all these methods is explained by the fact that 
each method has its own strengths and limitations. Although 
pharmacy dispensing data are objective, they only provide 
information about whether a patient fills their prescriptions 
and not so much whether a patient actually took their medi-
cation. Electronic monitoring of medication intake informs 
more precisely whether a patient took their medication, but 
it is costly and less feasible as it requires installment of a 
device in a patient’s home. Questionnaires are feasible and 
inexpensive but may be distorted by recall and social desir-
ability bias.
Hitherto, studies about the associations of different 
measures of medication adherence have been conducted at 
the overall group level. However, the often observed weak 
to moderate associations between these measures warrant 
an examination of distinct patient populations with dif-
ferent profiles on adherence measures. Methods that ena-
ble an identification of different patient populations (i.e. 
‘classes’) in a data-driven bottom-up manner may serve this 
goal. Here, we adopt one of these methods, called Latent 
Profile Analysis (LPA), to identify profiles on different 
measures of adherence. Compared to classifying individu-
als by face-validity or cluster-analysis, the LPA analysis is 
governed by so-called “goodness-of-fit” statistics. These 
provide an empirically based approach to assess the most 
likely number of patient classes with different adherence 
profiles. LPA or related approaches have been used to study 
amongst others adherence subtypes in hypertensive patients 
[4], depression subtypes among patients treated with citalo-
pram [5], examination of the nosological status of general-
ized anxiety disorders versus dysthymic disorder [6], and 
course trajectories of unipolar depressive disorders [7].
In this study, we applied LPA to examine profiles on 
different adherence measures among patients who are pre-
scribed antidepressants. These medications are frequently 
prescribed [8] and are an important therapeutic strategy for 
the long-term treatment of depression, anxiety, and other 
disorders [9]. At the same time, non-adherence to antide-
pressant therapy is substantial. Previous studies reported 
the incidence and prevalence of non-adherent patients to 
range from approximately one-third [10, 11] to half [12, 13] 
to about three in five [14] of the patients. Non-adherence 
to antidepressants is explained by previous findings show-
ing depression to actually be a predictor of non-adherence 
[15]. Non-adherence to antidepressants is also a clinically 
important problem as it was previously found to be asso-
ciated with an increased relapse risk [12]. Thus, like for 
other patient groups, proper measurement and detection of 
non-adherence among patients prescribed antidepressants is 
crucial. With regard to antidepressants, associations between 
different adherence measures were found to be mixed. Weak 
to moderate associations were found between self-reported 
adherence and electronic monitoring of medication intake 
[13, 14]. Associations between self-reported adherence and 
adherence based on pharmacy dispensing data were moder-
ate to strong [16]. Other researchers found weak associations 
between pill counts and plasma drug concentration [17].
Accordingly, using LPA the aim of the present study 
was to identify profiles on subjective and objective adher-
ence measures among patients who were prescribed 
antidepressants.
2  Methods
2.1  Study Design and Setting
Between April 2011 and April 2012, patients were enrolled 
through five community pharmacies of the Utrecht Phar-
macy Practice network for Education and Research (UPPER) 
that were located throughout the Netherlands [18]. All phar-
macies had automated dispensing records that contained 
information about patients’ sex, date of birth, dispensed 
medications, dispensing dates, type of prescriber, amount 
of medications dispensed, and prescribed dosages. The 
duration of antidepressant use was estimated by dividing 
the number of dispensed units by the prescribed number 
of units per day. All medications were coded according to 
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the Anatomical Therapeutic Chemical (ATC) classification 
index [19]. The reporting of study findings followed the 
ESPACOMP Medication Adherence Reporting Guideline 
(EMERGE) for medication adherence studies [20] and the 
STrengthening the Reporting of OBservational studies in 
Epidemiology (STROBE) criteria [21].
2.2  Participants
Patients were eligible if they were ≥ 18 years and if an anti-
depressant had been dispensed to them (selective serotonin 
reuptake inhibitors, ATC codes N06AB; non-selective mon-
oamine-oxydase inhibitors, N06AF; monoamine-oxydase 
inhibitors, N06AG; and other antidepressants, N06AX).
Patients were not included if they were dispensed tricyclic 
antidepressants (TCAs). TCAs are increasingly prescribed 
by physicians for conditions other than depression [22], 
which are often not documented in the automated pharmacy 
dispensing records [9]. Non-adherence was not an exclu-
sion criterion. Depending on the number of patients in a 
pharmacy who were dispensed antidepressants, every fourth 
or fifth patient was selected for participation. To prevent 
selection bias, patients were not selected by the pharmacist, 
but rather with the aid of the automated dispensing records 
by an impartial research assistant. Eligible patients received 
an invitation to participate in the study and a questionnaire 
about sociodemographic characteristics, medication use 
including previous use of antidepressants, disease character-
istics, self-reported adherence, and medication perceptions. 
Patients were requested to return the completed question-
naire within 2 weeks. In case of non-response, they were 
sent three reminders by mail. The index date was defined 
as the date on which the signed written informed consent 
and the questionnaire were received by the study team. 
Subsequently, patients were asked to get their antidepres-
sants dispensed in the Medication Event Monitoring System 
(MEMS) device during a period of 6 months (see below).
2.3  Adherence to and Perceptions 
about Antidepressant Therapy
Medication adherence was assessed by subjective and 
objective methods. The subjective measure included 
self-reported adherence as assessed with the Medication 
Adherence Rating Scale (MARS) [23]. The MARS was 
complemented by patients’ “perceived necessity” and 
“perceived concerns” about antidepressants as assessed 
with the Beliefs about Medicines Questionnaire (BMQ). 
Although the BMQ perceptions of “perceived necessity” 
and “perceived concerns” are not measures of adherence, 
they are likely to reflect patients’ willingness versus reluc-
tance to take their medicines [23]. Objective measures 
included electronic monitoring of medication intake using 
the MEMS (Aardex, Zug, Switzerland) and the Medica-
tion Possession Ratio (MPR) calculated from pharmacy 
dispensing data (see Fig. 1 for the time window during 
which the data for different adherence measures were col-
lected). In the literature, the authoritative ABC taxonomy 
of adherence distinguishes between three essential adher-
ence phases, namely “initiation”, “implementation”, and 
“persistence” [20, 24]. Based on the ABC taxonomy, the 
focus of the present study was mainly on the adherence 
phase of “implementation”.
The MARS consists of five items to assess the follow-
ing non-adherence behaviors: forget to take antidepressants, 
altering the dose, stop using antidepressants for a while, 
decide to skip a dose, and taking less antidepressants than 
prescribed. Patients had to rate each item on a 5-point scale 
(1 = always, 5 = never). Subsequently, these ratings were 
summated to obtain a total score with higher scores being 
indicative of better adherence (range 5–25). The BMQ con-
sists of items that are rated on a 5-point scale (1 = completely 
disagree, 5 = completely agree). Consensus has been reached 
that these items measure “perceived necessity,” e.g.: “My 
health at present depends on my antidepressants” (five items, 
range 5–25), and “perceived concerns,” e.g.: “I am afraid of 
the side effects of antidepressants” (six items, range 6–30).
The MEMS devices registered times and dates of occa-
sions on which patients had opened the medication vial, 
thereby enabling the monitoring of patients’ daily medica-
tion intake. All data from the MEMS devices were down-
loaded after the data collection period. From these MEMS 
data, we assessed the percentage of therapy days on which 
antidepressants were taken, i.e.: 100 − ((number of days 
missed/total number of MEMS days) × 100). Thus, higher 
percentages reflected better adherence.
Information on all dispensed medication to the patients 
was extracted from the automated dispensing records of the 
pharmacies. “Treatment episodes” were determined for each 
patient in the same way as described elsewhere [25]. Subse-
quently, we estimated the MPR for the last treatment episode 
prior to the index date or the “number of days’ supply between 
the first prescription within the treatment episode and the index 
date” divided by “the number of days elapsing between the first 
prescription within the treatment episode and the index date”. 
Higher MPR percentages reflected better adherence.
2.4  Statistical Analysis
Patients’ demographic and clinical characteristics were sum-
marized with descriptive statistics. MARS and BMQ scores 
were recalculated as percentages to facilitate mutual com-
parisons between these measures of adherence with the MPR 
and MEMS that were already calculated as percentages.
Using Latent Profile Analysis (LPA), we empirically 
examined patient populations (i.e. ‘classes’) with different 
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adherence profiles on the indicator variables of self-reported 
adherence (MARS), electronic monitoring of medication 
intake (MEMS), and adherence inferred from pharmacy 
dispensing data (MPR), as well as self-reported “per-
ceived necessity” and “perceived concerns” (BMQ). The 
BMQ measures were added as it was previously shown that 
increasing the number of indicator variables improved the 
stability of the LPA parameter estimates [26]. Identification 
of profiles occurred in a successive forward manner. First, 
we estimated an LPA model with a single class to which 
all patients were assigned. This corresponds to a standard 
statistical analysis of the total group. Subsequently, succes-
sive models were estimated in which “latent classes” were 
progressively added, one at a time. The most likely number 
of classes were those from the model with optimal statisti-
cal “goodness of fit”. For LPA, various “goodness of fit” 
statistics are available. As recommended previously [27], 
we inspected the Bayesian Information Criterion (BIC) and 
the Bootstrapped Likelihood Ratio Test (BLRT). In addi-
tion, we also inspected the Entropy. For the BIC, smaller 
values are indicative of better “goodness of fit”. The BLRT 
tests whether the current model with n latent classes has a 
better “goodness of fit” than the preceding model with n − 1 
latent classes. Improvement was deemed significant if the 
associated p value was < 0.05. The Entropy ranges from 0 
to 1 and is an indication of the quality of classification of 
individuals into classes. Entropy values > 0.8 are acceptable. 
To identify clinically relevant classes, alongside goodness 
of fit, classes had to contain at least 5% of study patients [6, 
7]. Because LPA is susceptible to converging on local rather 
than global solutions, we used multiple random starting val-
ues in estimating the LPA models (500 repeats with 20 final 
optimizations) [7]. Furthermore, the MARS, MEMS, and 
MPR variables seemed to be right-censored (with the distri-
butions lacking a right tail beyond the maximum score) and 
were therefore specified in the model accordingly.
In the primary LPA analysis, we included patients with 
complete data on all adherence measures (N = 131). In a 
secondary analysis, the LPA analysis was repeated with all 
221 patients of whom 90 who had complete data on the 
MARS, MPR, and BMQ measures but missing values on the 
MEMS. In LPA, missing values are dealt with by estimating 
parameters with maximum likelihood. After identification of 
latent classes, individuals were assigned to the most likely 
class using estimated class probabilities. The LPA analy-
sis was conducted using Mplus (version 7.4). Individuals 
from different latent classes of adherence measures were 
then compared on demographic and clinical characteristics 
in descriptive analyses using SPSS (version 24).
3  Results
3.1  Participants’ Characteristics
Of the 871 eligible patients who were approached, 221 
consented to participate. Three-quarters of patients were 
women, more than half were living with a partner, about half 
of the patients attained an intermediate educational level, 
and most patients were treated with paroxetine. About half 
of the patients were treated for depression as opposed to the 
remaining patients who were treated for anxiety, for depres-
sion with concomitant anxiety, or other disorders (Table 1).
3.2  Profiles of Adherence Measures
In the primary LPA analysis of patients with complete data 
on all adherence measures (N = 131), “goodness-of-fit” sta-
tistics (BIC, BLRT, Entropy) indicated that three classes of 
patients were most likely (Table 2). After plotting the mean 
scores of these three classes of patients on the adherence 
measures, the classes could be interpreted as a concordantly 
high adherent class (83%), which scored high on all adher-
ence measures and which had high BMQ necessity and low 
BMQ concerns; a concordantly suboptimal adherent class 
(11%) with lower scores on all adherence measures and 
lower BMQ necessity but comparable BMQ concerns; and 
a discordant class (6%) with high self-reported adherence 
on the MARS but lower adherence on objective measures 
of MEMS and MPR while exhibiting high BMQ necessity 
Fig. 1  Time window of data 












and low BMQ concerns (Fig. 2). Similar results were found 
in the secondary analysis in which the LPA analysis was 
repeated for all 221 patients including those 90 patients with 
complete data on the MARS, MPR, and BMQ measures but 
with missing values on the MEMS.
3.3  Descriptive Analyses of Profiles
Table 3 displays the demographic and clinical characteris-
tics of the three classes of patients with distinct adherence 
profiles. Compared to the concordantly high adherent class 
and concordantly suboptimal adherent class, patients in the 
discordant class were more often women, were younger, 
were less often living with a partner, less often had a high 
educational level, were less often using paroxetine, and had 
a depression diagnosis more often.
4  Discussion
We observed three distinct profiles on subjective and 
objective adherence measures in this sample of patients 
who were prescribed antidepressants. We found a large, 
concordantly high adherent class that was adherent on all 
measures and a concordantly suboptimal adherent class 
that had lower adherence on all measures. Interestingly, 
we also identified a small discordant class with high self-
reported adherence but lower adherence on objective 
measures of adherence and high “perceived necessity” and 
low “perceived concerns”.
Our findings are important as non-adherence is prevalent 
in patients treated with antidepressants [28]. We found that 
almost one in five patients could be considered non-adherent 
(i.e., the patients from the “concordantly suboptimal adher-
ent” and the “discordant” classes together). Previously, 
the incidence and prevalence of non-adherence were found 
to range from about one-third [10, 11] to half [12, 13] to 
three in five [14] of the patients. The present findings, and 
especially the finding of a discordant class of patients with 
high self-reported adherence but lower objectively meas-
ured adherence, are consistent with findings from a scoping 
review of studies in which the MEMS was compared with 
other adherence measures [29] as well as with findings from 
previous individual studies [1–3].
The identification of different adherence profiles and the 
detection of the discordant adherence class was enabled 
because adherence was measured using both subjective (self-
reported MARS) and objective measures (MEMS and MPR 
through pharmacy dispensing data). In studies, assessment 
of adherence is often limited to a single method particu-
larly self-report. Given the advantages and disadvantages 
of different adherence measures, multiple methods to assess 
therapy adherence are complementary. The MPR is primar-
ily a measure of long-term persistence to a particular medi-
cation or a class of medications while electronic monitoring 
is a measure of dosing regimen implementation to better 
understand patient habit of medication taking. Adoption 
of multiple assessment methods of adherence in research 
and clinical practice is likely to maximize accuracy [3, 15]. 
Our assessment of medication adherence with both subjec-
tive and objective methods is therefore the most important 
strength of this study.
A strength of the LPA is that it provides insight into the 
presence of relevant subpopulations of patients as was pre-
viously examined for hypertensive patients with regard to 
adherence to medications, diet, exercise, smoking, and blood 
pressure [4]. LPA provides a more formal approach to assess 
the most likely number of classes compared to methods such 
as cluster-analysis or classifying individuals by face-validity, 
because it is governed by “goodness-of-fit” statistics.
For clinical practice, these findings have two implica-
tions. First, clinicians should not solely rely on self-reported 
therapy adherence. Rather, they should seek verification of 
patients’ answers from for example pharmacy dispense data 
and the MPR calculated therefrom. Where there is not a 
closed pharmacy system such as with the Department of Vet-
erans Affairs Health Care System in the USA or the system 




 N (%) women 162 (73.3)
 M (SD) age, years 53.0 (14.6)
 N (%) with spouse/partner 117 (52.9)

















  Depression and concomitant anxiety 48 (22)
  Other condition 15 (7)
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of community pharmacies in the Netherlands, electronic 
monitoring of medication intake could be used to verify 
self-reported therapy adherence. Second, in line with the 
previous implication, implementation of feasible electronic 
monitoring of medication adherence in clinical practice is of 
paramount importance and should be expedited.
For research, adoption of multiple assessment meth-
ods of adherence enables investigation of the following 
Table 2  Parameters of fit of latent profile analysis (N = 131)
BLRT Bootstrapped Likelihood Ratio Test, BIC Bayesian Information Criterion
Class Maximum likeli-
hood
BIC Entropy BLRT test % of individuals in class
2 × LL differ-
ence
df p 1 2 3 4
1 – – – – – – – – – –
2 − 2265 4609 0.93 57.6 6 0.17 85 15 – –
3 − 2244 4596 0.97 42.2 6 0.048 11 6 83 –
4 − 2235 4606 0.96 18.7 6 0.49 11 6 4 79
Fig. 2  Scoring profiles of patient classes on adherence measures. 
*Values on adherence measures are expressed as percentages to 
facilitate mutual comparisons between different adherence measures. 
MARS Medication Adherence Rating Scale, MEMS Medication Event 
Monitoring System, MPR Medication Possession Ratio
Table 3  Demographic and clinical characteristics of patients from three adherence profiles
a Paroxetine vs. fluoxetine, fluvoxamine, sertraline, citalopram, venlafaxine, escitalopram, and other/unknown
b Depression vs. anxiety, depression and concomitant anxiety, or other condition
Characteristics Adherence profiles
Concordant high adherent 
(N = 109)
Concordant suboptimal adherent 
(N = 15)
Discordant (N = 7)
Demographic characteristics
 N (%) women 85 (78) 10 (67) 7 (100)
 M (SD) age, years 51.3 (13.8) 53.1 (13.1) 42.9 (14.8)
 N (%) with spouse/partner 79 (73) 13 (87) 4/(57)
 N (%) with high educational level 33 (30) 6 (40) 1 (14)
Clinical characteristics
 N (%) with paroxetine  usea 41 (38) 8 (53) 1 (14)
 N (%) with depression  diagnosisb 52 (48) 2 (13) 4 (57)
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opportunities. First, it would be worthwhile to conduct a sen-
sitivity analysis in which a discordant or otherwise atypical 
class as revealed by LPA may be left out, after which the pri-
mary analysis is repeated. Second, more research is needed 
about the prevalence and characteristics of the discordant 
class. The discordant pattern may represent distortions of 
self-reported adherence by social desirability, perhaps recall 
problems owing to cognitive impairment, or the intention 
to be adherent as in self-report versus actual non-adherence 
according to electronic monitoring or a combination of these 
possible explanations. It may therefore be valuable to con-
duct qualitative interviews [30] with individuals to examine 
reasons for such a discordance.
A number of methodological issues deserve to be 
addressed. First of all, although our sample size was mod-
erate, it comprised more than 100 participants. Previously, 
a Monte Carlo simulation study demonstrated that a sample 
size of 100 participants was sufficiently large to conduct an 
LPA analysis, taking into consideration also that electronic 
monitoring of medication intake constitutes a high-quality 
measure [26]. Having said this, replications in larger sam-
ples could still be fruitful, especially with regard to com-
paring identified classes on demographic and clinical char-
acteristics. Second, with regard to the sampling, selection 
bias may have occurred in the sense that adherent patients 
were more likely to participate. As a result, the sizes of the 
concordant suboptimal adherent and discordant classes may 
have been underestimated. However, it should also be noted 
that even so a substantial number of participating patients 
still had a lower adherence according to MEMS. Third, with 
regard to the adherence assessments, potential instrumen-
tation effects may have occurred, for example monitoring 
of medication intake with the MEMS may have improved 
adherence at least in some patients. Given that the MPR and 
MARS were assessed before the installment of the MEMS 
in patients’ homes, these measures were not affected by 
possible instrumentation effects of the MEMS. Naturally, 
to detect instrumentation effects, future research would need 
to adopt a factorial design where half of the participants 
would have all adherence measures monitored during the 
same time period while others would have not. Fourth, other 
adherence measures as inferred from the MEMS are worth-
while considering. Fifth, with regard to the ABC taxonomy 
[20, 24] of successive phases of adherence, namely “initia-
tion,” “implementation,” and “persistence,” it is noteworthy 
that our study was mainly focused on the “implementation” 
phase of antidepressant use. We had no data on prescrip-
tions and could therefore not study the “initiation” or early-
use phase in which a patient fills a prescription. Incorpo-
rating the “initiation” phase could therefore be valuable to 
examine if there are yet other distinct profiles on subjective 
and objective adherence measures among newly diagnosed 
patients or patients in the early treatment phase.
Taken together, we found distinct adherence profiles 
among patients who were prescribed antidepressants. This 
emphasizes the need to measure adherence through multi-
ple subjective and objective methods. Gaining more insights 
into the prevalence and characteristics of these different 
classes and in particular the discordant class is warranted.
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